Biofortuna Ltd is pleased to announce a record year of growth for its IVD Contract Services division. This growth has been driven by the expansion of its service portfolio, together with increased demand for its core lyophilisation services.
Biofortuna Ltd, a diagnostics company based in Wirral UK, announces significant investment into its IVD Contract Manufacturing Division in order to support continued growth.
Biofortuna’s new climate control system will allow for accurate control of environmental factors down to 5% relative humidity, resulting in unrivalled stability of lyophilised reagents. Packing in a low humidity environment ensures products are stored under optimal conditions for long-term, ambient temperature stability. 5% relative humidity also provides ideal conditions in which to pack lyophilised products and ensure there is no degradation of product during the packing procedures.
Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market.
World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company a strong focus for growth and efficiency. The breadth of the company’s portfolio of IVD manufacturing and development services has expanded to include manufacturing, dispensing, kitting, labelling, capping, as well as design and development of molecular diagnostic kits. …
UK based molecular diagnostics company Biofortuna has appointed a new Chairman to lead the next phase of growth.
Life sciences expert Ian Johnson will take on the role at Biofortuna with previous Chairman Mark Hurley remaining on the board as a Non-executive Director.
Biofortuna, based in the Wirral, specialises in proprietary freeze-dried diagnostics and …
Biofortuna Ltd, the UK based molecular diagnostics company specialising in its proprietary freeze-dried diagnostics and contract services, announces raising £1.5m in its latest funding round.
The £1.5m funding was supported by all the company’s current investors; Foresight VCTs, Catapult Ventures, Enterprise Ventures, MSIF, private investors and management.
The new funding is for Biofortuna to develop a portfolio of new molecular diagnostic …